Multiple Myeloma
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
Conference Coverage
Ruxolitinib overcame lenalidomide resistance in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
News
World Trade Center responders face greater cancer burden, including greater risk of multiple myeloma
The prevalence of multiple myeloma precursor disease was more than threefold higher in WTC exposed firefighters.
News
More evidence links increased BMI to higher multiple myeloma risk
MM risk rose almost 30% for every 5 kg/m2 increase in young adult BMI.
News
In myeloma, third ASCT is a viable option
The analysis identifies relapse-free interval as a prognostic factor.
Article
Treatment and Management of Multiple Myeloma
A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
Article
Meningococcal Arthritis Masking as Possible Myeloma
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.
News
Continue to opt for HDT/ASCT for multiple myeloma
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
